Business
AbbVie Completes Acquisition of Gilgamesh Pharmaceuticals' Bretisilocin
AbbVie (NYSE: ABBV) announced today that it has completed its acquisition of Gilgamesh Pharmaceuticals' lead investigational candidate, bretisilocin.
About this update from Abbvie Inc.
[{"type":"list","items":[{"val":[{"type":"text","content":"Acquisition expands AbbVie's psychiatry pipeline with the addition of a next-generation psychedelic compound currently in Phase 2 development for the treatment of major depressive disorder (MDD).","length":204,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":204,"olType":false},{"type":"text","content":"NORTH CHICAGO, Ill., Oct. 17, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that it has completed its acquisition of Gilgamesh Pharmaceuticals' lead investigational candidate, bretisilocin.","length":209,"tagName":"p"},{"type":"text","content":"Bretisilocin is a novel, short-acting serotonin 5-HT2A receptor agonist and 5-HT releaser currently in Phase 2 clinical development for the treatment of patients with moderate-to-severe major depressive disorder (MDD). This next-generation 5-HT2A receptor agonist is designed to help address current development challenges observed with classic psychedelic compounds.","length":367,"tagName":"p"},{"type":"text","content":""Recent clinical results have demonstrated the potential of bretisilocin to treat patients living with MDD," said Daniel Mikol, M.D., Ph.D., vice president, neuroscience development, AbbVie. "With the acquisition now complete, we look forward to accelerating the development of this next-generation compound, reinforcing AbbVie's commitment to delivering innovative, science-driven treatment options for people living with serious mental health conditions."","length":486,"tagName":"p"},{"type":"text","content":"For additional background on the acquisition, please read the press release announcing the definitive agreement under which AbbVie will acquire bretisilocin here.","length":167,"tagName":"p"},{"type":"text","content":"About AbbVie","length":12,"tagName":"p"},{"type":"text","content":"AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, oncology, neuroscience and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn,&nb...